Idéal Investisseur
Français English
CAC 40 : Market closed
8 365,01 pts
-0.05%


Last updated : 16/11/2026 - 17h14
🏠 Home   ➤    Stock news

DBV Technologies shares fall 4.5%, among the biggest decliners in the SBF 120

The Châtillon-based biotech falls sharply while the Paris index remains stable. The decline comes a few days after new clinical data presented in the United States, in a regulatory file still under review.


DBV Technologies shares fall 4.5%, among the biggest decliners in the SBF 120

A decline that contrasts with a virtually unchanged Paris market

The stock loses 4.47% to €1.88, while the SBF 120 gains 0.01% and the CAC 40 gains 0.04%. It ranks among the largest declines in the index, behind Eramet, Inventiva and Nanobiotix. This session's decline follows that of Friday, which was already negative, but the stock still holds a gain of 15.77% over one month.

Over three months, it remains down 20.58%. The analyses of the VITESSE study, presented at the ACAAI congress in Phoenix, concerned the severity of allergic reactions under Viaskin Peanut in children aged 4 to 7.

The biotech is listed on two markets: the Nasdaq ADS represents five ordinary shares in Paris, and the Paris-listed share remains eligible for the PEA.

Between its MA20 and MA50, the stock keeps a margin above its support

The price is above the MA20 (€1.84, a gap of +2.12%), but below the MA50 (€1.91, a gap of -1.62%). This position, between the two averages, reflects a rebound that has not yet resumed its medium-term trend. The support at €1.57 remains at a good distance, as does the resistance at €2.13.

On the regulatory front, the company indicated, when publishing its results for the first nine months of 2026 (on October 28, 2026), that it expected an FDA decision in the fourth quarter for the Viaskin Peanut patch in children aged 4 to 7, with a request for priority review. It also flagged a doubt about its going concern and a need for capital beyond the third quarter of 2027.

According to the declarations consulted, net short positions total 3.02% of the share capital, spread across four funds and nearly stable over thirty days (+0.03 points). This level, which exceeds 3%, shows that a modest fraction of the capital remains positioned to the downside, without any notable acceleration.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours